For most of the last hundred years, a malaria vaccine was the thing that could not be done. The parasite is a shapeshifter with a life cycle built to dodge the immune system, and trial after trial came back with numbers too low to matter. Generations of researchers spent careers getting close and falling short. It became the field's white whale.
This month the European Patent Office handed its 2026 European Inventor Award, in the research category, to the man who finally landed it: Sir Adrian Hill of the University of Oxford, for the R21/Matrix-M vaccine [1][2]. The ceremony was in Berlin. The achievement is on the ground in about 20 countries.
The number that matters is the efficacy. In clinical trials, R21/Matrix-M showed roughly 75 to 80 percent protection - clearing the World Health Organization's 75 percent target, a bar no malaria vaccine had ever cleared [1][2]. That is the line the whole century of near-misses could not cross, crossed.
What turns an efficacy number into saved lives is everything around it, and this is where the vaccine is almost quietly remarkable. It costs less than three euros a dose - about 2.50 pounds [1][3]. It stays stable for up to two years under standard refrigeration, which means it does not need the exotic cold chain that keeps other vaccines from reaching rural clinics [1]. A shot that is cheap and keeps in an ordinary fridge is a shot that actually arrives where malaria is. The WHO recommended it for widespread use in 2023; Ghana was among the first countries to approve it; the rollout now spans roughly 20 nations [2][3].
The stakes are the reason the white whale was worth a century of chasing. Malaria still kills a child somewhere in the world about every minute, the great majority of them under the age of five. A vaccine that is 80 percent effective, costs the price of a coffee, and survives in a normal refrigerator is precisely the kind of tool that bends that line downward - preventing, by the accounts of those tracking the rollout, tens of thousands of deaths [3].
An inventor's prize is a marker, not a finish line, and malaria is not beaten. What the award records is direction. After a hundred years of a vaccine that was always a decade away, there is one in the fridge in 20 countries, working, at a price the places that need it can pay - and this month, the world stopped to say so.
